Nautilus Biotechnology 3Q 2026: Revenue $234K, Net loss ($15.64M), EPS ($0.12) — 10-Q Summary

What happened

Nautilus Biotechnology reported third-quarter 2026 revenue of $234K versus no revenue a year earlier, while its net loss widened to $15.64M from $13.57M and diluted loss per share was $0.12 versus $0.11.

Confirmed

Global impact / market context

The new revenue came from a research grant and paid proteomics services, not instrument sales, so it does not yet show repeatable product demand. A wider net loss means the company is spending more cash than it earns while it prepares Voyager pre-orders and initial shipments.

Analyst inference

Nautilus is a pre-commercial life science tools company, which means its value rests on future instrument sales rather than current revenue. Delays in Broadscale assay development and a shift toward proteoform applications could change how investors judge the timing of that future revenue.

Analyst inference

What to watch

1. Nautilus plans to open Voyager pre-orders in early 2027, with initial instrument shipments expected around midyear, which is the first real test of whether customers will commit money to the platform. Confirmed
2. Initial commercial assays are expected to include Tau, AKT1 and another oncology proteoform assay, with blood samples targeted for future expansion. Watch whether these assays reach general availability on schedule. Proposed
3. Broadscale assay development is behind the pace needed for general availability in 2027, so watch whether the shift toward proteoform applications produces paid service revenue or further delays the path to product sales. Analyst inference

Evidence

• Original source link unavailable